163 related articles for article (PubMed ID: 28636657)
21. Induction of gene amplification as a gain-of-function phenotype of mutant p53 proteins.
El-Hizawi S; Lagowski JP; Kulesz-Martin M; Albor A
Cancer Res; 2002 Jun; 62(11):3264-70. PubMed ID: 12036943
[TBL] [Abstract][Full Text] [Related]
22. Apoptosis induced by chamaejasmine in human osteosarcoma cells through p53 pathway.
Yang D; Wang P; Ren X
Tumour Biol; 2015 Jul; 36(7):5433-9. PubMed ID: 25677904
[TBL] [Abstract][Full Text] [Related]
23. Silencing of Glucose Transporter Protein-1 by RNA Interference Inhibits Human Osteosarcoma Mg63 Cells Growth in vivo.
Jian F; Yuan F; Jiong M; Zhu XZ; Yu GR; Lu DD
Technol Cancer Res Treat; 2015 Apr; 14(2):243-8. PubMed ID: 24502553
[TBL] [Abstract][Full Text] [Related]
24. Bone environment is essential for osteosarcoma development from transformed mesenchymal stem cells.
Rubio R; Abarrategi A; Garcia-Castro J; Martinez-Cruzado L; Suarez C; Tornin J; Santos L; Astudillo A; Colmenero I; Mulero F; Rosu-Myles M; Menendez P; Rodriguez R
Stem Cells; 2014 May; 32(5):1136-48. PubMed ID: 24446210
[TBL] [Abstract][Full Text] [Related]
25. ErbB3 silencing reduces osteosarcoma cell proliferation and tumor growth in vivo.
Jullien N; Dieudonné FX; Habel N; Marty C; Modrowski D; Patino A; Lecanda F; Sévère N; Marie PJ
Gene; 2013 May; 521(1):55-61. PubMed ID: 23541807
[TBL] [Abstract][Full Text] [Related]
26. Alternate splicing of the p53 inhibitor HDMX offers a superior prognostic biomarker than p53 mutation in human cancer.
Lenos K; Grawenda AM; Lodder K; Kuijjer ML; Teunisse AF; Repapi E; Grochola LF; Bartel F; Hogendoorn PC; Wuerl P; Taubert H; Cleton-Jansen AM; Bond GL; Jochemsen AG
Cancer Res; 2012 Aug; 72(16):4074-84. PubMed ID: 22700878
[TBL] [Abstract][Full Text] [Related]
27. Regulation of the P53 tumor suppressor gene and the Mcl-2 oncogene expression by an active herbal component delivered through a smart thermo-pH-sensitive PLGA carrier to improve Osteosarcoma treatment.
Akbari P; Taebpour M; Akhlaghi M; Hasan SH; Shahriyari S; Parsaeian M; Haghirosadat BF; Rahdar A; Pandey S
Med Oncol; 2024 Jan; 41(3):68. PubMed ID: 38289404
[TBL] [Abstract][Full Text] [Related]
28. Aptamer-functionalized hybrid nanoparticle for the treatment of breast cancer.
Powell D; Chandra S; Dodson K; Shaheen F; Wiltz K; Ireland S; Syed M; Dash S; Wiese T; Mandal T; Kundu A
Eur J Pharm Biopharm; 2017 May; 114():108-118. PubMed ID: 28131717
[TBL] [Abstract][Full Text] [Related]
29. Pla2g16 phospholipase mediates gain-of-function activities of mutant p53.
Xiong S; Tu H; Kollareddy M; Pant V; Li Q; Zhang Y; Jackson JG; Suh YA; Elizondo-Fraire AC; Yang P; Chau G; Tashakori M; Wasylishen AR; Ju Z; Solomon H; Rotter V; Liu B; El-Naggar AK; Donehower LA; Martinez LA; Lozano G
Proc Natl Acad Sci U S A; 2014 Jul; 111(30):11145-50. PubMed ID: 25024203
[TBL] [Abstract][Full Text] [Related]
30. Multidrug resistance protein 1 silencing in osteosarcoma and chondrosarcoma cell lines.
Freund SS; Bendtsen MM; Safwat A; Joergensen PH
J Cancer Res Ther; 2023 Apr; 19(Supplement):S278-S284. PubMed ID: 37148005
[TBL] [Abstract][Full Text] [Related]
31. Functional studies of a novel germline p53 splicing mutation identified in a patient with Li-Fraumeni-like syndrome.
Piao J; Sakurai N; Iwamoto S; Nishioka J; Nakatani K; Komada Y; Mizutani S; Takagi M
Mol Carcinog; 2013 Oct; 52(10):770-6. PubMed ID: 22495821
[TBL] [Abstract][Full Text] [Related]
32. [Expression of Ether à go-go 1 and its molecular mechanism of regulating the malignant phenotype of osteosarcoma].
Chen ZD; Liu QJ; Zeng WR; Wu XY; Lin B; Wu J
Zhonghua Zhong Liu Za Zhi; 2016 Nov; 38(11):818-825. PubMed ID: 27998439
[No Abstract] [Full Text] [Related]
33. Non-genotoxic activation of p53 through the RPL11-dependent ribosomal stress pathway.
Morgado-Palacin L; Llanos S; Urbano-Cuadrado M; Blanco-Aparicio C; Megias D; Pastor J; Serrano M
Carcinogenesis; 2014 Dec; 35(12):2822-30. PubMed ID: 25344835
[TBL] [Abstract][Full Text] [Related]
34. Silencing LPAATβ inhibits tumor growth of cisplatin-resistant human osteosarcoma in vivo and in vitro.
Song L; Duan P; Gan Y; Li P; Zhao C; Xu J; Zhang Z; Zhou Q
Int J Oncol; 2017 Feb; 50(2):535-544. PubMed ID: 28035350
[TBL] [Abstract][Full Text] [Related]
35. Relationship between P-glycoprotein expression and p53 status in high-grade osteosarcoma.
Serra M; Maurici D; Scotlandi K; Barbanti-Brodano G; Manara MC; Benini S; Picci P; Bertoni F; Bacci G; Sottili S; Baldini N
Int J Oncol; 1999 Feb; 14(2):301-7. PubMed ID: 9917506
[TBL] [Abstract][Full Text] [Related]
36. Tim-3 facilitates osteosarcoma proliferation and metastasis through the NF-κB pathway and epithelial-mesenchymal transition.
Feng ZM; Guo SM
Genet Mol Res; 2016 Sep; 15(3):. PubMed ID: 27706678
[TBL] [Abstract][Full Text] [Related]
37. Silver nanoparticles defeat p53-positive and p53-negative osteosarcoma cells by triggering mitochondrial stress and apoptosis.
Kovács D; Igaz N; Keskeny C; Bélteky P; Tóth T; Gáspár R; Madarász D; Rázga Z; Kónya Z; Boros IM; Kiricsi M
Sci Rep; 2016 Jun; 6():27902. PubMed ID: 27291325
[TBL] [Abstract][Full Text] [Related]
38. Investigations on a clinically and functionally unusual and novel germline p53 mutation.
Rutherford J; Chu CE; Duddy PM; Charlton RS; Chumas P; Taylor GR; Lu X; Barnes DM; Camplejohn RS
Br J Cancer; 2002 May; 86(10):1592-6. PubMed ID: 12085209
[TBL] [Abstract][Full Text] [Related]
39. Design of an inhalable dry powder formulation of DOTAP-modified PLGA nanoparticles loaded with siRNA.
Jensen DK; Jensen LB; Koocheki S; Bengtson L; Cun D; Nielsen HM; Foged C
J Control Release; 2012 Jan; 157(1):141-8. PubMed ID: 21864597
[TBL] [Abstract][Full Text] [Related]
40. [Knockdown of cyclin A2 expression by small interfering RNA in MG-63 cells].
Liu Y; Ding JY; Shen WL; Zhao X; Fan SW
Zhonghua Zhong Liu Za Zhi; 2007 Sep; 29(9):670-5. PubMed ID: 18246796
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
